1. A 66-year-old woman with Parkinson's disease has been on pramipexole 1 mg three times daily for 8 months. At her follow-up visit she reports bilateral ankle swelling that began approximately 6 weeks ago. Examination confirms bilateral pitting edema to the mid-shin. Her blood pressure is 118/74 mmHg, heart rate 68 bpm, and a recent echocardiogram obtained for an unrelated reason showed normal cardiac function. She has no history of heart failure, venous insufficiency, or hypoalbuminemia. Which of the following is the most appropriate initial management of her edema?
A) Add furosemide 20 mg daily, which is the first-line treatment for dopamine agonist-induced peripheral edema and reliably resolves the fluid retention within 2 to 3 weeks without requiring any change to the pramipexole dose
B) Discontinue pramipexole immediately and switch to levodopa, since peripheral edema is an indication that pramipexole has exceeded its therapeutic window and continued use risks progression to cardiac failure
C) Reduce the pramipexole dose, as peripheral edema is a recognized class adverse effect of dopamine agonists reflecting peripheral vasodilation and altered capillary permeability; dose reduction is the appropriate first intervention and diuretics are generally not effective and not recommended as primary management
D) Order a lower-extremity venous duplex ultrasound and refer to vascular surgery before making any medication change, since dopamine agonist-induced edema cannot be clinically distinguished from deep vein thrombosis and anticoagulation may be required
E) Reassure the patient that bilateral ankle edema is an expected and benign feature of Parkinson's disease itself rather than a drug effect, and continue pramipexole unchanged with compression stockings as the only intervention needed
ANSWER: C
Rationale:
Peripheral edema affecting the legs and ankles is a recognized class adverse effect of dopamine agonists, occurring in approximately 10 to 15% of patients. The mechanism reflects peripheral vasodilation and altered capillary permeability mediated by dopamine receptor activity in peripheral vasculature. In this patient, the temporal relationship between pramipexole initiation and edema onset, combined with the absence of cardiac, hepatic, or venous causes, makes drug-induced edema the most likely diagnosis. The appropriate first intervention is pramipexole dose reduction, which often leads to resolution or substantial improvement. Diuretics are generally not effective for dopamine agonist-induced edema and are not recommended as primary management — the edema is not sodium-retentive in the conventional diuretic-responsive sense. Option C is correct.
Option A: Option A is incorrect because diuretics are specifically noted to be generally ineffective and not the recommended primary management for dopamine agonist-induced peripheral edema; adding furosemide without addressing the causative agent is not the appropriate first step.
Option B: Option B is incorrect because peripheral edema alone does not indicate that pramipexole has exceeded its therapeutic window or that cardiac failure is imminent; immediate discontinuation without first attempting dose reduction is not warranted, and the echocardiogram confirms normal cardiac function.
Option D: Option D is incorrect because while deep vein thrombosis should be considered in appropriate clinical contexts, bilateral symmetric ankle edema appearing gradually over 6 weeks in a patient on a dopamine agonist with no other risk factors does not require immediate vascular referral before any medication adjustment; the clinical picture is consistent with drug-induced edema and should be managed accordingly.
Option E: Option E is incorrect because peripheral edema is not an expected feature of Parkinson's disease itself — it is a drug adverse effect attributable to the dopamine agonist; attributing it to the disease and continuing unchanged without dose adjustment misses the treatable pharmacological cause.
2. A 58-year-old man with recently diagnosed Parkinson's disease is started on ropinirole immediate-release. At his 6-week follow-up, his motor control remains suboptimal despite dose titration to what would be considered an adequate dose in most patients. He reports smoking 20 cigarettes daily and has no intention of quitting. His renal and hepatic function are normal. Which of the following best explains why this patient may require a higher ropinirole dose than a non-smoking patient to achieve equivalent plasma concentrations and motor benefit?
A) Nicotine directly activates dopamine D2 receptors in the striatum, competitively blocking ropinirole binding and requiring higher ropinirole doses to displace nicotine from the receptor and achieve therapeutic occupancy
B) Cigarette smoke contains carbon monoxide that reduces cerebral blood flow, impairing ropinirole delivery to the striatum and requiring higher doses to achieve adequate central drug concentrations despite normal plasma levels
C) Smoking accelerates gastric emptying, increasing the rate of ropinirole absorption and paradoxically lowering peak plasma concentrations by distributing the dose over a shorter absorption window, necessitating more frequent dosing rather than higher individual doses
D) Nicotine inhibits renal tubular secretion of ropinirole, reducing its renal clearance and paradoxically lowering plasma concentrations through a feedback mechanism that suppresses hepatic CYP1A2 synthesis in proportion to renal drug accumulation
E) Cigarette smoke contains polycyclic aromatic hydrocarbons that induce CYP1A2 — the hepatic enzyme primarily responsible for ropinirole metabolism — substantially increasing ropinirole clearance and reducing systemic drug exposure at any given dose; this patient may therefore require higher doses than a non-smoker to achieve equivalent plasma concentrations and therapeutic effect
ANSWER: E
Rationale:
Ropinirole is metabolized primarily by hepatic CYP1A2. Cigarette smoke — specifically the polycyclic aromatic hydrocarbon component, not nicotine itself — is a potent inducer of CYP1A2. In active smokers, CYP1A2 induction substantially accelerates ropinirole metabolism, reducing systemic drug exposure at any given dose compared with a non-smoker receiving the same dose. As a result, this patient may require higher ropinirole doses than standard to achieve plasma concentrations equivalent to those in a non-smoking patient, and his suboptimal motor control despite an apparently adequate dose is consistent with CYP1A2 induction reducing his effective drug exposure. Prescribers should be aware of this interaction and titrate based on clinical response rather than assuming standard doses will produce standard plasma concentrations in active smokers. Option E is correct.
Option A: Option A is incorrect because nicotine does not directly activate D2 receptors and does not compete with ropinirole for striatal D2 receptor binding; ropinirole's poor motor control in this patient reflects reduced systemic drug exposure, not receptor-level competition.
Option B: Option B is incorrect because carbon monoxide-mediated reduction in cerebral blood flow is not a recognized pharmacokinetic mechanism reducing ropinirole delivery to the striatum; the interaction is entirely hepatic and metabolic, not cerebrovascular.
Option C: Option C is incorrect because smoking does not accelerate gastric emptying in a manner that clinically reduces ropinirole peak concentrations through a shortened absorption window; the pharmacokinetic interaction is at the level of hepatic CYP1A2-mediated drug elimination, not gastrointestinal absorption.
Option D: Option D is incorrect because ropinirole is not significantly eliminated by renal tubular secretion — it is hepatically cleared via CYP1A2; and there is no feedback mechanism by which renal drug accumulation suppresses hepatic CYP1A2 synthesis; the premise of option D conflates pramipexole's renal elimination with ropinirole's hepatic elimination.
3. A 72-year-old man with advanced Parkinson's disease and frequent unpredictable off episodes is being set up for subcutaneous apomorphine rescue therapy. His neurologist plans to admit him for the first test dose in 5 days. Which of the following correctly describes the antiemetic pretreatment protocol that must be initiated before the first apomorphine dose is administered?
A) Domperidone 20 mg three times daily should be started 3 days before the planned first apomorphine dose and continued through the titration period; this allows sufficient time for domperidone to establish peripheral D2 receptor blockade in the gut and chemoreceptor trigger zone, preventing the nausea and vomiting that would otherwise accompany apomorphine initiation
B) Ondansetron 8 mg twice daily should be started the morning of the first apomorphine dose, as 5-HT3 blockade provides reliable and immediate antiemetic coverage without any requirement for lead-in dosing
C) No antiemetic pretreatment is required if the apomorphine dose is titrated slowly, beginning at 1 mg subcutaneous and increasing by 1 mg increments every 30 minutes; the slow titration approach eliminates emetogenic stimulation at the chemoreceptor trigger zone without pharmacological pretreatment
D) Metoclopramide 10 mg three times daily should be started 48 hours before the first apomorphine dose, as it is the most effective peripherally acting antiemetic available and provides reliable protection against apomorphine-induced nausea through combined D2 and 5-HT4 receptor activity in the gut
E) Prochlorperazine 5 mg twice daily should be started 3 days before the first apomorphine dose; as the antiemetic with the longest clinical track record in Parkinson's disease, it provides the most reliable protection against apomorphine-induced nausea and is preferred over domperidone in patients over 70 years
ANSWER: A
Rationale:
Antiemetic pretreatment is mandatory when initiating subcutaneous apomorphine therapy because apomorphine is a potent emetogen, particularly during the first weeks of treatment before tolerance develops. The standard protocol requires domperidone 20 mg three times daily to be started 3 days before the planned first apomorphine injection. This lead-in period allows domperidone to establish effective peripheral D2 receptor blockade at the chemoreceptor trigger zone — which lies outside the blood-brain barrier — and in the gastrointestinal tract, preventing the nausea and vomiting that would otherwise occur with the first doses. Domperidone is the antiemetic of choice because it does not cross the blood-brain barrier and therefore does not block the central dopamine D2 receptors that apomorphine must activate for its antiparkinsonian effect. Option A is correct.
Option B: Option B is incorrect because ondansetron and all 5-HT3 antagonists are specifically contraindicated with apomorphine due to reports of severe hypotension and loss of consciousness with the combination; ondansetron must never be used as the antiemetic for apomorphine initiation regardless of dosing timing.
Option C: Option C is incorrect because slow dose titration alone does not eliminate apomorphine's emetogenic effect; antiemetic pretreatment is required regardless of the titration schedule, and the protocol mandates pharmacological pretreatment before the first dose rather than relying on gradual dose escalation to manage nausea.
Option D: Option D is incorrect because metoclopramide is specifically contraindicated in Parkinson's disease; it crosses the blood-brain barrier and blocks central D2 receptors, directly antagonizing the antiparkinsonian effect of dopaminergic therapy and worsening motor function — it must never be used as an antiemetic in PD patients regardless of its peripheral activity.
Option E: Option E is incorrect because prochlorperazine is a phenothiazine antipsychotic with potent central D2 antagonism; it is contraindicated in Parkinson's disease for the same reason as metoclopramide, and it has no established role as a preferred antiemetic for apomorphine initiation in any age group.
4. A 67-year-old woman with Parkinson's disease on levodopa-carbidopa 25/100 mg four times daily has persistent wearing-off fluctuations. Her neurologist adds ropinirole as adjunctive therapy and titrates it over 6 weeks to an effective dose. The patient reports good improvement in her off time but now develops nausea, dizziness, and involuntary movements of her arms in the afternoons — coinciding with her peak levodopa dose. Which of the following best describes what has occurred and how it should be managed?
A) The ropinirole has induced CYP enzymes responsible for levodopa metabolism, increasing levodopa plasma concentrations above the therapeutic range; the correct response is to discontinue ropinirole and return to levodopa monotherapy
B) The patient has developed ropinirole tolerance, in which the motor benefit of the agonist has diminished and the adverse effects now predominate; the correct response is to increase the ropinirole dose to restore motor benefit and accept the nausea as a transient side effect
C) The involuntary movements represent ropinirole-specific dyskinesias caused by the agonist's D3 receptor activity in the motor striatum; since levodopa does not cause dyskinesias at the doses being used, the ropinirole dose should be halved
D) The addition of ropinirole has produced combined dopaminergic stimulation that now exceeds the threshold for peak-dose dyskinesias and adverse effects at her existing levodopa dose; the correct response is to reduce the levodopa dose — typically by 10 to 30% — to bring the total dopaminergic input back within the therapeutic range while maintaining the agonist for its off-time reduction benefit
E) The patient has developed serotonin syndrome from the combined serotonergic activity of levodopa and ropinirole; the levodopa should be immediately discontinued and the patient monitored for autonomic instability and hyperthermia
ANSWER: D
Rationale:
When a dopamine agonist is added to an established levodopa regimen, the combined dopaminergic stimulation from both agents frequently exceeds the patient's individual threshold for peak-dose adverse effects — including dyskinesias, nausea, and dizziness — even though the levodopa dose was previously well tolerated. This is a predictable and expected pharmacodynamic consequence of combination therapy, not a drug toxicity or treatment failure. The correct response is to reduce the levodopa dose, typically by 10 to 30%, to bring the total dopaminergic input back within the therapeutic range. The agonist is maintained because it provides the off-time reduction benefit that was the indication for adding it. This dose-sparing effect on levodopa — allowing levodopa reduction without loss of overall motor control — is in fact one of the established clinical advantages of agonist adjunct therapy. Option D is correct.
Option A: Option A is incorrect because ropinirole does not induce hepatic enzymes responsible for levodopa metabolism in a clinically significant way, and it does not increase levodopa plasma concentrations through enzyme induction; the adverse effects reflect pharmacodynamic combined dopaminergic excess, not a pharmacokinetic interaction.
Option B: Option B is incorrect because the clinical picture does not represent ropinirole tolerance — the patient has improved off time, confirming the agonist is working, and the adverse effects represent excessive total dopaminergic stimulation rather than loss of agonist efficacy.
Option C: Option C is incorrect because the involuntary movements are dyskinesias from combined peak-dose dopaminergic excess, not an agonist-specific phenomenon mediated by D3 activity in the motor striatum; the appropriate dose reduction target is levodopa, not ropinirole.
Option E: Option E is incorrect because serotonin syndrome is not caused by the pharmacological combination of levodopa and ropinirole; neither agent is a serotonin reuptake inhibitor or serotonin releaser in the classical sense, and the clinical presentation — peak-dose dyskinesias and nausea coinciding with levodopa dosing — is entirely consistent with dopaminergic excess rather than serotonergic toxicity.
5. A 61-year-old man with Parkinson's disease has been on ropinirole extended-release for 4 months. He presents to his neurologist after a minor motor vehicle collision. He reports that he fell asleep suddenly at the wheel without any prior warning or drowsiness — the last thing he remembers is pulling onto the highway. He had no chest pain, palpitations, or focal neurological symptoms before the event. Which of the following best describes the appropriate immediate clinical response and patient counseling?
A) Reassure the patient that a single episode of drowsiness at the wheel is not specifically related to ropinirole, arrange brain MRI to exclude a seizure focus or structural lesion, and permit continued driving pending the neuroimaging result
B) Recognize this as a probable ropinirole-induced sudden sleep attack — a recognized class adverse effect of dopamine agonists; advise the patient to cease driving immediately until the episode has been evaluated and managed, reduce or adjust the ropinirole dose, and counsel him that sudden irresistible sleep onset without warning can recur and that driving before clearance poses serious risk to himself and others
C) Attribute the event to Parkinson's disease-related autonomic dysfunction causing a vasovagal episode at the wheel; initiate fludrocortisone for orthostatic hypotension and continue ropinirole unchanged, since the motor benefit outweighs the driving risk in a patient who is still employed
D) Increase the ropinirole dose, as subtherapeutic dopaminergic stimulation in Parkinson's disease causes fragmented nocturnal sleep that spills into daytime somnolence; achieving better motor control with a higher dose will improve sleep architecture and eliminate the daytime sleepiness
E) Discontinue ropinirole immediately and permanently, since a sleep attack while driving constitutes an absolute contraindication to any future dopamine agonist use, and transition the patient to levodopa monotherapy without further evaluation of the episode
ANSWER: B
Rationale:
Sudden sleep attacks — episodes of irresistible sleep onset without preceding warning or drowsiness — are a recognized and potentially dangerous class adverse effect of dopamine agonists. They have been reported during driving with serious consequences, including motor vehicle collisions. The event described by this patient — sudden sleep onset without warning while driving — is the clinical signature of a dopamine agonist-induced sleep attack rather than a vasovagal event, seizure, or Parkinson's disease manifestation. The immediate clinical response requires: first, advising the patient to cease driving until the situation is fully evaluated and managed, because recurrence is possible and unpredictable; second, reviewing and reducing the ropinirole dose; and third, explicit counseling that sudden sleep can recur without warning and that continued driving before clearance poses serious risk. This is both a clinical safety obligation and a medicolegal responsibility. Option B is correct.
Option A: Option A is incorrect because this event should not be attributed to non-specific drowsiness awaiting neuroimaging; the clinical features are consistent with a dopamine agonist-induced sleep attack requiring immediate medication review and driving restriction, not observation pending MRI results while driving continues.
Option C: Option C is incorrect because the event is not consistent with vasovagal syncope — there was no prodrome, no loss of muscle tone or consciousness from a vasovagal mechanism, and no positional component; fludrocortisone treats orthostatic hypotension, not sleep attacks, and continuing ropinirole unchanged without driving restriction after a sleep attack while driving is unsafe.
Option D: Option D is incorrect because increasing the ropinirole dose is contraindicated in a patient who has just had a sleep attack attributable to the agonist; higher doses increase, not decrease, the risk of excessive daytime somnolence and sleep attacks.
Option E: Option E is incorrect because permanent discontinuation of all dopamine agonists is not mandated by a single sleep attack; the appropriate response is dose adjustment and driving restriction with reassessment, and some patients can continue agonist therapy safely after the episode is managed, depending on response to dose reduction.
6. A 78-year-old retired teacher presents with a 6-month history of right-hand resting tremor, bradykinesia, and rigidity. He is diagnosed with Parkinson's disease. His Mini-Mental State Examination score is 26/30 — within normal limits but with mild difficulty on the delayed recall subtask. He lives alone and drives independently. A neurology resident suggests initiating a dopamine agonist using an agonist-first strategy to delay dyskinesia development. Which of the following best explains why levodopa rather than a dopamine agonist is the preferred initial therapy in this patient?
A) Levodopa is preferred because this patient's tremor-predominant presentation responds better to levodopa's D1 receptor activity than to the D2-preferential profile of non-ergot agonists, making the tremor the decisive pharmacological factor rather than age or cognition
B) Levodopa is preferred because patients over 75 years have reduced peripheral aromatic amino acid decarboxylase activity, making them dependent on higher levodopa doses to achieve central dopaminergic effect, and dopamine agonists cannot compensate for this enzymatic deficiency
C) In patients over approximately 70 years — particularly those with any degree of cognitive vulnerability, as evidenced by this patient's delayed recall difficulty — the adverse effect risks of dopamine agonists (cognitive worsening, excessive somnolence, confusion, impulse control disorders, and fall risk) outweigh the dyskinesia-delay benefit, especially given his shorter expected disease course and his living situation; levodopa is the preferred initial agent in this age group
D) Levodopa is preferred because dopamine agonists are absolutely contraindicated in patients over 70 years due to a demonstrated dose-independent risk of fatal cardiac arrhythmia in this age group, a risk that does not apply to levodopa
E) Levodopa is preferred because the dyskinesia-delay benefit of agonist-first therapy applies only to patients under 50 years of age; in patients between 50 and 70 years the benefit is marginal, and in patients over 70 it is absent because older patients develop fewer dyskinesias with levodopa than younger patients regardless of initial drug choice
ANSWER: C
Rationale:
The rationale for agonist-first therapy rests on a specific risk-benefit calculation that is highly age-dependent. In younger patients — typically under approximately 60 years with preserved cognition — the dyskinesia-delay benefit of several years justifies the adverse effect risks because the patient has a long expected disease course and will live with the consequences of early dyskinesias for decades. In patients over approximately 70 years, this calculation reverses: dopamine agonists carry substantially elevated risks of cognitive worsening, excessive somnolence, confusion, falls, and impulse control disorders in older patients and those with pre-existing cognitive vulnerability. This patient is 78 years old, lives alone, and drives — making confusion and somnolence particularly dangerous — and already shows mild delayed recall difficulty that signals cognitive vulnerability to agonist adverse effects. The expected disease course is shorter, reducing the clinical benefit of delaying dyskinesias by a few years. Levodopa is better tolerated cognitively in older patients and remains the most effective antiparkinsonian agent. Option C is correct.
Option A: Option A is incorrect because while tremor-predominant PD may respond somewhat better to levodopa, the primary determinant of the initial drug choice in this case is the patient's age and cognitive status, not the tremor phenotype; D1 receptor activity is not the decisive pharmacological factor in the levodopa-versus-agonist decision for older patients.
Option B: Option B is incorrect because reduced peripheral aromatic amino acid decarboxylase activity in elderly patients is not an established mechanism mandating higher levodopa doses or precluding agonist use; this is a pharmacologically fabricated rationale that does not reflect established prescribing principles.
Option D: Option D is incorrect because dopamine agonists are not absolutely contraindicated above age 70 on the basis of fatal cardiac arrhythmia; the age-related caution is based on adverse effect risk-benefit balance, not a dose-independent cardiac arrhythmia risk.
Option E: Option E is incorrect because the dyskinesia-delay benefit of agonist-first therapy is not limited to patients under 50 years — the evidence base includes patients up to approximately 60 to 65 years — and the reason for preferring levodopa in older patients is the adverse effect profile, not the absence of dyskinesia risk reduction.
7. A 69-year-old man with Parkinson's disease has been maintained on cabergoline for 7 years, having been started on it before non-ergot alternatives were widely available in his region. He remains on cabergoline because multiple attempts to transition him to pramipexole have caused intolerable nausea. He is otherwise well with no dyspnea, orthopnea, or peripheral edema. Which of the following correctly identifies the mandatory surveillance requirement for this patient given his ongoing cabergoline use?
A) No additional monitoring is required beyond standard PD follow-up, since cabergoline-associated valvulopathy occurs only in patients taking doses above 3 mg daily and this patient's dose for PD is below this threshold
B) Annual thyroid function tests are required because cabergoline suppresses TSH through dopamine D2 receptor agonism in the anterior pituitary, and subclinical hypothyroidism develops in the majority of patients on long-term cabergoline therapy
C) Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement every 6 months is the recommended surveillance strategy for cabergoline-induced valvulopathy, and echocardiography is reserved only for patients with elevated NT-proBNP or new symptoms
D) Annual pulmonary function testing with diffusing capacity measurement is required because cabergoline's 5-HT2B receptor activation causes progressive pleuropulmonary fibrosis before cardiac valve involvement, and respiratory surveillance detects early fibrosis before it becomes clinically significant
E) Periodic echocardiographic surveillance is mandatory for this patient to detect early fibrotic valvulopathy and valvular regurgitation; cabergoline activates 5-HT2B receptors on cardiac valve interstitial fibroblasts and the resulting restrictive valvulopathy is dose-dependent and cumulative, making ongoing cardiac monitoring essential in patients who cannot be transitioned to a non-ergot agonist
ANSWER: E
Rationale:
Cabergoline is an ergot-derived dopamine agonist that activates 5-HT2B receptors on cardiac valve interstitial fibroblasts, stimulating fibroblast proliferation and producing a restrictive valvulopathy with regurgitation that is pathologically identical to the valve disease caused by fenfluramine and pergolide. This valvulopathy is dose-dependent and cumulative, meaning that risk increases with total cabergoline exposure over time. For patients with Parkinson's disease who cannot be transitioned to a non-ergot agonist and must remain on cabergoline, periodic echocardiographic surveillance is mandatory to detect early valvular changes before they become clinically significant — asymptomatic valvular regurgitation can progress silently without symptoms such as dyspnea or edema. The absence of symptoms in this patient does not exclude subclinical valvular disease that may already be present after 7 years of cabergoline. Option E is correct.
Option A: Option A is incorrect because there is no established safe dose threshold for cabergoline valvulopathy in PD; even doses used for Parkinson's disease — which are lower than doses used for hyperprolactinemia — have been associated with significant echocardiographic abnormalities in 20 to 30% of patients in surveillance studies, and a 3 mg daily threshold does not appear in established monitoring guidelines.
Option B: Option B is incorrect because cabergoline does suppress prolactin through D2 receptor agonism in the anterior pituitary, but annual thyroid function testing is not the mandatory surveillance requirement for cabergoline-treated PD patients; the cardiac valvulopathy risk, not thyroid suppression, drives the monitoring requirement.
Option C: Option C is incorrect because NT-proBNP measurement is not the recommended primary surveillance strategy for cabergoline-induced valvulopathy; echocardiography is the direct and standard method for detecting valvular regurgitation and structural changes, and reserving it for elevated biomarkers would miss subclinical valvular disease that is the target of surveillance.
Option D: Option D is incorrect because while pleuropulmonary fibrosis is a recognized complication of ergot alkaloids, it is not the primary early complication requiring systematic surveillance in cabergoline-treated PD patients; cardiac valvulopathy through 5-HT2B receptor activation is the dominant fibrotic complication requiring echocardiographic monitoring, and pulmonary fibrosis does not typically precede valvular disease as a rule requiring sequential organ surveillance.
8. A 75-year-old woman with Parkinson's disease has persistent visual hallucinations and paranoid delusions. Her agonist dose has been reduced without adequate improvement in psychosis. She has received quetiapine at optimized doses for 10 weeks with minimal benefit. Her neurologist decides to initiate clozapine. Which of the following correctly describes the safety monitoring program that must be established before and during clozapine therapy?
A) Clozapine requires enrollment in the Clozapine Risk Evaluation and Mitigation Strategy (REMS) program due to the risk of agranulocytosis; absolute neutrophil count (ANC) must be monitored weekly for the first 6 months, biweekly for the following 6 months, and monthly thereafter once the patient is stable — dispensing is contingent on current monitoring results, and clozapine must be withheld if the ANC falls below defined thresholds
B) Clozapine requires monthly fasting glucose and lipid panel monitoring for the first year because it causes severe insulin resistance and hypertriglyceridemia in the majority of PD patients within the first 6 months; hematological monitoring is not required because agranulocytosis risk applies only to patients under 60 years of age
C) Clozapine requires weekly echocardiography for the first 3 months because its muscarinic receptor antagonism causes acute cardiomyopathy in approximately 5% of elderly patients; after 3 months without cardiac events the monitoring frequency can be reduced to monthly
D) No additional monitoring beyond standard clinical assessment is required for clozapine in PD patients, because the doses used for PD psychosis (typically 6.25 to 50 mg daily) are substantially lower than the doses used in schizophrenia and agranulocytosis has not been reported at these low doses in published PD trials
E) Clozapine requires baseline and weekly complete blood count with differential for the first year, then monthly indefinitely; unlike the standard Clozapine REMS program, PD patients receive a modified monitoring schedule with less frequent testing because the low doses used in PD confer a substantially reduced agranulocytosis risk compared with psychiatric doses
ANSWER: A
Rationale:
Clozapine use in any indication — including Parkinson's disease psychosis at low doses — requires enrollment in the Clozapine REMS program in the United States. The program mandates absolute neutrophil count monitoring because clozapine carries a risk of potentially fatal agranulocytosis in approximately 1 to 2% of patients. The monitoring schedule is: weekly ANC for the first 6 months, biweekly for months 7 through 12, and monthly thereafter in patients who remain stable. Dispensing pharmacies are required to verify that current monitoring results meet defined ANC thresholds before releasing each prescription — clozapine cannot be dispensed without current monitoring data. If the ANC falls below defined thresholds, clozapine must be withheld and the patient monitored more intensively. This monitoring requirement applies regardless of the dose being used. Option A is correct.
Option B: Option B is incorrect because hematological monitoring is not age-restricted to patients under 60 years; the agranulocytosis risk and the REMS monitoring requirement apply to all patients on clozapine regardless of age, and metabolic monitoring for glucose and lipids, while clinically prudent, is not the primary or mandatory REMS requirement.
Option C: Option C is incorrect because weekly echocardiography is not a component of clozapine monitoring; while clozapine has been associated with myocarditis and cardiomyopathy in a small proportion of patients — typically in the first month — this is monitored clinically and with targeted cardiac evaluation when symptoms suggest it, not by routine weekly echocardiography.
Option D: Option D is incorrect because agranulocytosis has been reported with low-dose clozapine in PD patients, and the REMS monitoring requirement applies at all doses without a low-dose exemption; the claim that monitoring is not required at PD doses is incorrect and potentially dangerous.
Option E: Option E is incorrect because there is no modified PD-specific Clozapine REMS schedule with reduced monitoring frequency; the monitoring schedule is the same regardless of indication or dose, and the standard REMS program applies fully to PD patients.
9. A 71-year-old man with advanced Parkinson's disease has been on continuous subcutaneous apomorphine infusion (CSAI) for 22 months with excellent motor control — his off time has decreased by approximately 65% and his levodopa dose has been reduced by 40%. However, he now has multiple firm subcutaneous nodules at former infusion sites across his abdomen and thighs, and the remaining viable infusion areas are becoming limited. Which of the following best describes the management of this complication and the advanced therapy option available if site limitation becomes prohibitive?
A) The nodules represent a Coombs-positive hemolytic immune reaction to apomorphine; CSAI must be discontinued immediately and the patient transitioned to oral dopamine agonist therapy, as continued subcutaneous apomorphine exposure will cause progressive hemolytic anemia
B) The nodules are caused by apomorphine's acidic pH damaging subcutaneous tissue; the solution is to alkalinize the infusion solution by adding sodium bicarbonate to the reservoir, which eliminates the tissue reaction and allows continued infusion at existing sites without rotation
C) The nodules represent a class effect of subcutaneous drug delivery and are not specific to apomorphine; the appropriate response is to switch to a different subcutaneous medication such as subcutaneous levodopa, which does not cause nodule formation because it has a neutral pH
D) Skin nodules and subcutaneous indurations at infusion sites are the principal long-term limiting adverse effect of CSAI, developing in most patients with prolonged use; management includes systematic rotation of infusion sites across all available body areas and ultrasound-guided site selection to identify viable subcutaneous tissue; if site availability becomes prohibitive despite these measures, transition to levodopa-carbidopa intestinal gel (LCIG) delivered via percutaneous endoscopic gastrojejunostomy provides an alternative continuous dopaminergic delivery strategy
E) The nodules will resolve spontaneously within 3 to 6 months if the patient takes a scheduled 2-week break from CSAI every 6 months, during which oral dopamine agonist therapy provides bridging coverage; this planned interruption strategy is the standard approach to nodule management in CSAI-treated patients
ANSWER: D
Rationale:
Subcutaneous skin nodules and indurations are the principal long-term limiting adverse effect of continuous subcutaneous apomorphine infusion, developing in most patients with prolonged use as cumulative tissue trauma from the infusion cannula causes fibrotic reactions at injection sites. These nodules progressively restrict the number of viable infusion areas, eventually becoming a practical barrier to continued CSAI. The established management approach has two components: first, systematic rotation of infusion sites across all available body areas — abdomen, thighs, upper arms — to distribute tissue trauma; and second, ultrasound-guided assessment and selection of sites with adequate subcutaneous tissue depth and tissue viability. When site availability becomes prohibitive despite these measures, levodopa-carbidopa intestinal gel (LCIG) delivered via percutaneous endoscopic gastrojejunostomy tube represents the established alternative continuous dopaminergic delivery strategy, providing equivalent continuous stimulation without subcutaneous tissue dependence. Option D is correct.
Option A: Option A is incorrect because Coombs-positive hemolytic anemia is a recognized but rare complication of long-term CSAI, distinct from the skin nodule complication described; nodules are a fibrotic site reaction, not an immune hemolytic process, and the patient's presentation does not suggest hemolytic anemia.
Option B: Option B is incorrect because alkalinizing the apomorphine infusion solution with sodium bicarbonate is not the standard management for nodule formation; apomorphine must be maintained at an acidic pH for stability, and alkalinization would degrade the drug — this approach is pharmacologically unsound and not an established clinical practice.
Option C: Option C is incorrect because subcutaneous levodopa formulations exist but are not a standard alternative in this setting; the clinical recommendation for CSAI site limitation is either optimized rotation and ultrasound guidance or transition to LCIG, not substitution with subcutaneous levodopa.
Option E: Option E is incorrect because planned 2-week interruptions of CSAI every 6 months for nodule management is not an established standard of care; the correct approach is continuous optimized site rotation and ultrasound guidance, with LCIG as the escalation option, not scheduled drug holidays.
10. A 52-year-old man with Parkinson's disease on pramipexole 3 mg daily (in divided doses) develops severe hypersexuality that is causing significant relationship harm. His neurologist reduces pramipexole to 1.5 mg daily, but within 10 days he develops disabling bradykinesia, rigidity, and freezing that prevent him from working. Returning to 3 mg daily promptly restores motor function. He refuses to stop pramipexole entirely. Which of the following best describes the pharmacologically appropriate next steps in managing this clinical dilemma?
A) Add sildenafil and refer to sex therapy; the hypersexuality is best managed by channeling the behavior rather than pharmacologically suppressing it, and the motor benefit of maintaining pramipexole 3 mg daily outweighs any pharmacological intervention targeting the impulse control disorder
B) The clinical tension between ICD control requiring lower agonist doses and motor function requiring higher doses represents a genuine management dilemma; options include referral for deep brain stimulation evaluation — which can improve motor function sufficiently to allow agonist dose reduction — and addition of clozapine at low dose, which has been used to reduce agonist requirements in some patients; the goal is to create pharmacological space for agonist dose reduction without unacceptable motor deterioration
C) Add an SSRI at the maximum licensed dose and maintain pramipexole at 3 mg daily; SSRIs reliably suppress dopamine agonist-induced hypersexuality through competitive serotonergic inhibition of mesolimbic D3 receptor signaling and are the first-line pharmacological treatment for ICD in patients who cannot tolerate agonist dose reduction
D) Switch immediately from pramipexole to levodopa at a levodopa equivalent dose, since levodopa does not activate mesolimbic D3 receptors and therefore carries no ICD risk; the switch eliminates the ICD while maintaining equivalent motor benefit at the same dopamine equivalent dose
E) Maintain pramipexole at 3 mg daily and refer the patient to a behavioral medicine specialist for cognitive behavioral therapy (CBT); randomized controlled trials have established CBT as a definitive treatment for dopamine agonist-induced ICDs that produces complete remission in the majority of patients without any change in dopaminergic therapy
ANSWER: B
Rationale:
This case illustrates the core clinical dilemma of ICD management when the patient is motor-dependent on the agonist dose that is causing the ICD. The pharmacological primary intervention — agonist dose reduction — is not feasible without unacceptable motor deterioration, and the patient refuses complete discontinuation. Two management strategies are pharmacologically rational in this setting. First, deep brain stimulation of the subthalamic nucleus improves motor function through a mechanism independent of dopamine receptor stimulation; postoperatively, the agonist dose can often be substantially reduced while maintaining adequate motor control, creating the pharmacological space for ICD resolution. Second, clozapine at low doses has been used in this context — clozapine's D3 receptor activity in the mesolimbic system may attenuate the reward-sensitizing component of the ICD, and it can also allow modest agonist dose reduction in some patients. Both strategies aim to reduce the mesolimbic D3 receptor overactivation driving the ICD while preserving striatal dopaminergic motor function. Option B is correct.
Option A: Option A is incorrect because behavioral channeling of hypersexuality is not an established or appropriate pharmacological management strategy for dopamine agonist-induced ICD; the ICD is pharmacologically driven by D3 mesolimbic overactivation, and managing its consequences rather than its cause is not an adequate clinical response to a recognized drug adverse effect causing relationship harm.
Option C: Option C is incorrect because SSRIs do not reliably suppress dopamine agonist-induced ICDs through competitive serotonergic inhibition of D3 signaling; the mesolimbic D3 pathway is dopaminergic, not serotonergic, and SSRIs are not established first-line pharmacological treatment for this indication at any dose.
Option D: Option D is incorrect because levodopa-derived dopamine does stimulate D3 receptors in the mesolimbic system — levodopa acts at all dopamine receptor subtypes including D3 — and switching to levodopa at an equivalent dose does not eliminate the ICD risk; ICDs occur with levodopa as well as agonists, though the D3 preferential affinity of pramipexole makes it a particularly prominent driver.
Option E: Option E is incorrect because CBT has not been established as a definitive treatment producing complete ICD remission in the majority of patients without medication change in randomized controlled trials; CBT is an adjunctive behavioral support strategy, not a pharmacological substitute for addressing the causative drug mechanism.
11. A 64-year-old woman with Parkinson's disease has been stable on pramipexole immediate-release (IR) 0.5 mg three times daily (total daily dose 1.5 mg) for 18 months. At a routine visit, her neurologist converts her to pramipexole extended-release (ER) for dosing convenience, but writes the prescription as pramipexole ER 1.5 mg three times daily — the same number of tablets and same individual tablet dose as her IR regimen. Three days later she calls with severe nausea, dizziness, and somnolence. Which of the following best explains her symptoms and identifies the correct corrective action?
A) She is experiencing an allergic reaction to an excipient in the pramipexole ER formulation that is not present in the IR tablet; the correct action is to discontinue pramipexole ER and return to pramipexole IR while allergy testing is arranged
B) The pramipexole ER formulation has higher oral bioavailability than IR because the extended-release matrix prevents first-pass hepatic metabolism; her symptoms result from increased systemic drug exposure at the same total daily dose, and she should be switched to a lower-bioavailability agonist such as ropinirole
C) The prescription was written incorrectly: pramipexole ER conversion from IR maintains the same total daily dose administered once daily — her correct ER prescription is 1.5 mg once daily, not 1.5 mg three times daily; the error has tripled her total daily dose to 4.5 mg, causing symptoms of pramipexole toxicity; the correct action is to reduce her pramipexole ER to 1.5 mg once daily
D) The symptoms are unrelated to the dose conversion and represent a viral illness; pramipexole IR and ER are bioequivalent at the same total daily dose administered in the same dosing frequency, and tripling the frequency of pramipexole ER relative to IR produces no pharmacokinetic difference because the extended-release matrix automatically adjusts the rate of drug release to match the total intended daily dose regardless of how many tablets are taken
E) The pramipexole ER formulation has a longer half-life than IR because the extended-release matrix creates a depot effect in the gastrointestinal tract; the correct conversion requires reducing the total daily dose by 50% when switching from IR to ER to account for this depot accumulation, meaning her correct ER prescription should be 0.75 mg once daily
ANSWER: C
Rationale:
The conversion from pramipexole IR to ER uses the same total daily dose administered once daily rather than in divided doses. This patient's stable and well-tolerated IR regimen was 0.5 mg three times daily — a total daily dose of 1.5 mg. The correct ER prescription is pramipexole ER 1.5 mg once daily. Instead, the prescription was written as 1.5 mg three times daily — applying the individual IR dose frequency to the ER formulation — which results in a total daily dose of 4.5 mg, three times the intended and previously tolerated dose. The symptoms of severe nausea, dizziness, and somnolence appearing within days of the conversion are classic signs of pramipexole dose-related toxicity at the tripled dose. The corrective action is immediate reduction to pramipexole ER 1.5 mg once daily, which restores the original total daily dose and should resolve the toxicity symptoms within days. Option C is correct.
Option A: Option A is incorrect because formulation excipient allergies causing nausea, dizziness, and somnolence within 3 days of a drug conversion in a patient with no prior allergy history are far less likely than dose-related toxicity from the prescription error; the symptoms are entirely consistent with dopaminergic excess at triple the intended dose.
Option B: Option B is incorrect because pramipexole ER does not have higher oral bioavailability than IR due to first-pass metabolism prevention; pramipexole's oral bioavailability is approximately 90% for both formulations because it undergoes minimal first-pass hepatic metabolism regardless of release rate, and switching to ropinirole is not indicated.
Option D: Option D is incorrect because the extended-release matrix does not automatically adjust the dose release rate to cap the total daily dose regardless of tablets taken; each 1.5 mg ER tablet delivers 1.5 mg over 24 hours, and taking three such tablets delivers 4.5 mg over 24 hours — the tripled dose is genuine and pharmacokinetically consequential, not self-correcting.
Option E: Option E is incorrect because pramipexole ER conversion from IR does not require a 50% dose reduction; the established conversion maintains the same total daily dose, and reducing to 0.75 mg once daily would under-dose the patient at half her previously effective dose.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.